Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-02-12
2008-08-05
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211100, C514S211120, C514S211140, C514S215000, C514S217000, C514S220000, C540S545000, C540S547000, C540S548000, C540S554000, C540S557000, C540S558000, C540S560000, C540S561000, C540S562000, C540S577000, C540S578000, C540S586000
Reexamination Certificate
active
07407949
ABSTRACT:
Novel compounds according to general formula 1, wherein G1is NR5R6or a fused polycyclic group that are specific OT receptor agonists and/or V1areceptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.
REFERENCES:
patent: 5760031 (1998-06-01), Albright
patent: WO 02/083682 (2002-10-01), None
patent: WO 03/000692 (2003-01-01), None
patent: WO 03/016316 (2003-02-01), None
International Search Report of PCT/EP2004/001304.
Thomas Bossmar et al., “Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions”, British Journal of Obstetrics & Gynaecology, Apr. 1997, vol. 104, pp. 471-477.
R. Brouard et al., “Effect of SR49059 an orally active V1avasopressin receptor antagonist, in the prevention of dysmenorrhoea”, British Journal of Obstetrics & Gynaecology, May 2000, vol. 107, pp. 614-619.
Venkatesan Aranapakam et al., '4,10-Dihydro-5H-Thieno[3,2-c][1]Benzazepine Derivatives and 9,10-Dihydro-4H-Thieno[2,3-C][1]Benzazepine Derivatives as Orally Active Arginine Vasopressin Receptor Agonists, Bioorganic & Medicinal Chemistry Letters 9 (1999) pp. 1733-1736.
M. Artico et al., “Ricerche su Sostanze ad Attivita Antiblastica”, II Fármaco., Ed. Sc. vol. 24, No. 3, pp. 276-284, Mar. 1969.
F. Chimenti et al., “Ricerche su Sostanze ad Attivita Antiblastica”, II Fármaco, Ed. Sc. vol. 32, No. 5, pp. 339-347, May 1977.
Jiban K. Chakrabarti et al., “4-piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics”, J. Med. Chem. 1980, 23, pp. 878-884.
Jiban K. Charabarti et al., “10-Piperazinyl-4H-thieno[3,2-b][1,5]- and-[3,4-b][1,5]benzodiazepines as Potential Neuroleptics”, J. Med. Chem. 1980, 23, pp. 884-889.
Jiban K. Charabarti et al., Synthesis and Pharmacological Evaluation of a Series of 4-Piperazinylpyrazolo[3,4-b]- and-[4,3-b][1,5]benzodiazepines as Potential Anxiolytics, J. Med. Chem. 1989, 32, pp. 2573-2582.
Alba Chimirri et al., “Annelated 1,5-Benzodiazepines. Part I. Three, Four, and Five Membered Rings”, Heterocycles, vol. 36, No. 3, 1993, pp. 601-637.
Gary L. Gunewald et al., “Effect of Ring Size or an Additional Heteroatom on the Potency and Selectivity of Bicyclic Benzylamine-Type Inhibitors of Phenylethanolamine N-Methyltransferase”, J. Med. Chem. 1996, 39, 3539-3546.
Janice M. Klunder et al., “Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones”, J. Med. Chem., 1992, 35, pp. 1887-1897.
Jean-Françoise F. Liégeois et al., “Pyridobenzoxazepine and Pyridobenzothiazepine Derivates as Potential Central Nervous System Agents: Synthesis and Neurochemical Study”, J. Med. Chem. 1994, 37, pp. 519-525.
Timothy O. Olagbermiro et al., “Alkylation and an Unusual Reductive Ring Opening of Some Thieno[3,4-b][1,5]benzoxazepin-10-ones”, Department of Chemistry, Bayero University, Kano, Nigeria, vol. 19, Nov.-Dec. 1982, pp. 1501-1504.
William B. Wright Jr. et al., “Derivatives of 11-(1-Piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as Central Nervous Systems Agents”, J. Med. Chem. 1980, 23, pp. 462-465.
Satoru Sasatani et al., “Diisobutylaluminum Hydride a Novel Reagent for the Reduction of Oximes”, Tetrahedron Letters, vol. 24, No. 43, pp. 4711-4712, 1983.
Batt Andrzej Roman
Baxter Andrew John
Heeney Celine Marguerite Simone
Hudson Peter
Robson Peter Andrew
Coleman Brenda L
Ferring B.V.
Foley & Lardner
LandOfFree
Benzamide derivatives as oxytocin agonists and vasopressin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamide derivatives as oxytocin agonists and vasopressin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamide derivatives as oxytocin agonists and vasopressin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002595